HC Wainwright Increases Hemab Therapeutics (NASDAQ:COAG) Price Target to $52.00

Hemab Therapeutics (NASDAQ:COAG) had its price target increased by equities researchers at HC Wainwright from $40.00 to $52.00 in a report issued on Monday, Marketbeat Ratings reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 36.73% from the company’s previous close.

A number of other equities analysts also recently weighed in on the stock. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target on the stock. Zacks Research raised Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Wedbush started coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $42.00 target price for the company. Finally, Evercore began coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $43.80.

Hemab Therapeutics Stock Performance

Shares of Hemab Therapeutics stock opened at $38.03 on Monday. The business’s fifty day simple moving average is $28.51. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $38.87. The stock has a market cap of $1.78 billion and a price-to-earnings ratio of -1.59.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity at Hemab Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock in a transaction on Monday, May 4th. The shares were bought at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the purchase, the director directly owned 6,149,096 shares in the company, valued at $110,683,728. This trade represents a 77.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders bought a total of 2,970,541 shares of company stock worth $55,459,603 in the last 90 days.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.